Cytokinetics (CYTK) Liabilities and Shareholders Equity (2010 - 2026)

Cytokinetics (CYTK) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 0.75% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $5.4 billion (down 4.72% YoY), while the FY2025 annual figure was $1.4 billion, up 1.63% from the prior year.
• Liabilities and Shareholders Equity retreated to $1.3 billion in Q1 2026 per CYTK's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q2 2024 and bottomed at $740.6 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2022.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 31.17% — and 2024, when it surged 95.38%.
• Cytokinetics' Liabilities and Shareholders Equity stood at $1.0 billion in 2022, then declined by 18.77% to $824.3 million in 2023, then soared by 70.04% to $1.4 billion in 2024, then climbed by 1.63% to $1.4 billion in 2025, then fell by 10.6% to $1.3 billion in 2026.
• Business Quant data shows CYTK's Liabilities and Shareholders Equity at $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.